Company news

Fulcrum Therapeutics, Inc. news in 2022

Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

November 30, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2022

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

November 7, 2022

Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

November 6, 2022

Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8: 00 a.m. ET

November 1, 2022

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

October 31, 2022

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

October 11, 2022

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

September 5, 2022

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

August 15, 2022

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

August 14, 2022

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

August 10, 2022

Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8: 00 a.m. ET

August 3, 2022

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

July 10, 2022

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

July 4, 2022

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

June 9, 2022

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

May 11, 2022

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

May 8, 2022

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

May 4, 2022

Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8: 00 a.m. ET

May 1, 2022

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting

March 31, 2022

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

March 16, 2022

Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference

March 13, 2022

Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

March 2, 2022

Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

March 2, 2022

Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8: 00 a.m. ET

February 23, 2022

Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

January 9, 2022

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

January 3, 2022

Calls in 2022

Decks in 2022

  • AAN 2022

    Conference · 21 slides · Apr 5, 2022

  • AAN 2022

    Conference · 22 slides · April 2022